Triple-negative breast cancer (TNBC), in which the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) are not expressed [3, 4], accounts for approximately 170,000 of the 1 million breast cancer cases which are diagnosed worldwide annually [4]. Here, ERBB2 is linked to triple-negative breast carcinoma.